More than 50% of clinical trials currently fail due to low efficacy.
InSyBio is able to reduce the risk of failed trials through a two-step process which can be applied in early phase 1 clinical trials. During the first step – discovery – our multi-omics technology can effectively identify markers, signatures and efficacy/toxicity predictive models from a limited sample size. In step two – application in late phase 1 or phase 2 clinical trials – these markers and models may be used as a test to stratify patients for the participation in a study, thus excluding individuals for whom the drug or treatment will either be ineffective or likely to present adverse effects.